CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits.

This project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts .

The personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.

Eligibility criteria

Qualifiers

Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures

Negative personal history for melanoma

Less than 100 naevi

Less than 5 clinically atypical naevi

Disqualifiers

Presence of dermatological lesions requiring immediate treatment at the time of consultation.

History of solid organ transplantation (Organ Transplant Recipient, OTR).

Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes).

Failure to meet one or more of the inclusion criteria.

Trial design

Treatments tested in this trial

  • Verbal information only
  • Personalized Discharge Letter
  • Personalized Discharge Letter + IntelliStudio

Treatment groups

150 Participants
are divided into 3 treatment groups